Understanding NINLARO® (ixazomib)

There are two Ninlaro-based treatment options to be considered by patients who can benefit from an all-oral drug regimen. Ninlaro® (ixazomib) + Revlimid® (lenalidomide) + dexamethasone is a triplet (3-drug) combination known as IRd, approved by the FDA for the treatment of patients with myeloma who have received at least 1 prior therapy. Ninlaro + Pomalyst® (pomalidomide) + dexamethasone is a triplet therapy known as IPd, recommended in the NCCN Guidelines as a Category 1 treatment option for previously treated myeloma.